메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술대회자료
저자정보
Yun-Ju Chen (I-Shou University)
저널정보
한의병리학회 대한동의병리학회 학술대회논문집 2015 The Korean Society of Oriental Pathology International Symposium
발행연도
2015.10
수록면
131 - 154 (24page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
Hepatocellular carcinoma (HCC) is often diagnosed as an advanced state due to no obvious symptoms in the early stage, which leads to the high mortality rate. Although a multikinase inhibitor sorafenib (Nexavar®. BAY43-9006) is so far the standard treatment for advanced HCC, the therapeutic efficacy is not shown as predicted. It prompts us to develop alternative strategies for improvement of sorafenib therapy in HCC. Chrysin is proposed as a potent inhibitor of breast cancer resistance protein (BCRP/ABCG2), which functions as a mediator of drug efflux, to reverse BCRP-mediated multidrug resistance (MDR) to chemotherapy. Our previous study demonstrates that BCRP expression level affects the sensitivity of HCC cells to sorafenib. Co-treatment of chrysin greatly synergized the effect of sorafenib on the inhibition of HCC cell viability. Whether there is other mechanism than inhibition of drug efflux responsible for the synergistic effect of chrysin on sorafenib activity in HCC cells is still not clearly elucidated. It is reported that high basal phosphorylation level of ERK1/2 benefits the response of HCC cells to sorafenib both in vitro and in vivo. Our results showed that chrysin increased ERK1/2 phosphorylation level of HCC cells in both time- and dose-dependent manners. Furthermore, we found that chrysin-synergized antigrowth activity of sorafenib in HCC cells was enhanced by overexpression of MEK1, an upstream regulator of ERK1/2 phosphorylation. However, this synergistic effect was lost when MEK activity was blocked by either U0126 inhibitor or MEK1 siRNA, which suggests MEK1-ERK1/2 pathway as a critical role in this regulation. Further mechanism analysis revealed that overexpression of MEK 1 slowed the growth rate of HCC cells. Indeed, both sorafenib activity and phosphorylation of MEK1-ERK1/2 pathway were increased in HCC cells with medium containing lower percentage of serum. In parallel, chrysin could no longer have synergistic effect on sorafenib activity in FICC cells with medium containing lower percentage of serum. Taken together, these results suggest that sustained ERK1/2 phosphorylation by chrysin renders HCC cells exhibiting a slow-growth pattern, which in turn renders HCC cells more sensitive to sorafenib treatment. Chrysin may be as a potential sensitizer to elevate the anti-growth activity of sorafenib in HCC cells in the future.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-0101-2016-519-002373836